...findings, published as a preprint in The Lancet, are consistent with Friday’s correspondence in The Lancet...

...first and second doses.One study, reported Friday by Chaim Sheba Medical Centre and Tel Aviv University researchers in The Lancet...
...from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) rises quickly after the first dose. The second paper, also published in Lancet...
...to the window when vaccine-induced immune responses were building. New AstraZeneca dataAlso on Friday, a separate Lancet...

...against symptomatic disease caused by the B.1.1.7 (501Y.V1) variant first identified in the U.K. in a Lancet ...
...B.1.1.7 and 95.6% against the original variant.The variant-based paper also support findings reported Monday in a Lancet paper...

...registered the heterologous adenoviral vector vaccine to 18. The new authorizations were announced a day after The Lancet...

...problem of asymptomatic spread. The results, according to a Lancet...
...the boosterdose,” the authors wrote in the Lancet...
...down slightly from the 70.4% reported in Lancet...

...By Sandi Wong, Assistant Editor Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has...

...suggesting a 59.5% vaccine efficacy rate.The update is roughly comparable to data published in The Lancet...
...but drew its conclusion from the 86% of subjects received doses within the approved range.The Lancet...

...elderly individuals remains an open question. The Lancet...
...Sources: New England Journal of Medicine and Lancet Stephen...

...cases that was as long as 12 weeks in AZ’s clinical trials. Data published in The Lancet...
...was the observation that a longer interval between standard doses led to greater efficacy. The Lancet...

...details the unplanned protocol shifts complicating the pooled efficacy analysis of AstraZeneca and Oxford’s AZD1222.The Lancet...